-
Mid-term analysis of DESTINY-Lung01 in Phase II trials showed meaningful clinical activity in the treatment of HER2 mutant non-small cell lung cancer patients, with 61.9% of patients receiving tumor remission
Time of Update: 2020-06-06
The results of the ongoing Phase II clinical trial destinY-Lung01 show that AstraZeneca and The Third Of AstraZeneca have achieved clinical lying in patients with one or more systems treated with o
-
2020ASCO, Keystone Pharmaceuticals and Blueprint Medicines announce the latest research data from Pralsetinib
Time of Update: 2020-06-06
May 30, 2020, Blueprint Medicines, a partner of Keystone Pharmaceuticals (Suzhou) Co., Ltd ("Keystone Pharmaceuticals," HKEx Code: 2616), released the latest data from its ongoing RESEARCH on the S
-
Nat Med: CXCR4 Antagonists , PD-1 inhibitors , chemotherapy triple therapy for pancreatic cancer breakthrough
Time of Update: 2020-06-06
Data from the clinical trial COMBAT (KEYNOTE-202), recently released by of , show that the new CXCR4 inhibitor BL-8040 (Motixafortide), in combination with PD-1 inhibitors and chemotherapy, has init
-
ASCO 2020 . . . First-line treatment of liver cancer! The results of the test of the innovative drug Donatini, which was independently developed in China, were encouraging, and the median total survival period (mOS) reached 12.1 months.
Time of Update: 2020-06-06
May 30, 2020, Suzhou Zeyin Biopharmaceutical Co., Ltd (referred to as: Zeye Pharmaceuticals) announced: Dafini first-line treatment of advanced hepatocellular carcinoma clinical research ZGDH3, at t
-
ASCO2020 , new breakthrough in immunotherapy for lung squamous cancer, Baiji Shenzhou shows the value of China's "research"
Time of Update: 2020-06-06
May 29, 2020, the annual event of the global oncology community - the Annual Meeting of the American Society of Clinical Oncology (ASCO) officially opened, China's local biopharmaceutical company B
-
DESTINY-CRC01II clinical trials show that Enhertu treats HER2-positive metastatic colorectal cancer patients with tumor remission rate of 45.3%
Time of Update: 2020-06-06
The results of phase DESTINY-CRC01II clinical trials conducted by AstraZeneca and Phase 1301, , show that Enhertu (trastuzumab deruxtecan), or DS-8201) is used in PATIENTs with HER2-positive, non-reprectable and/or metastatic colorectal cancer who have received two or more standard treatments in the past, with clinical significance.
-
A major breakthrough in the treatment of liver cancer! The first cancer immunization program: Roche Tecentriq and Avastin (Special Sanqi and Anvidin) are approved by the FDA!
Time of Update: 2020-06-06
May 31, 2020 / prnewswire BIOON/ -- Roche recently announced that the U.S Food and Drug Administration ( FDA ) has approved the anti-PD-L1 therapy Tecentriq (Special, generic name: atez) Olizumab,
-
Immunotherapy can significantly extend survival time in patients with advanced bowel cancer
Time of Update: 2020-06-06
June 2, 2020 /PRNewswire/--- A large international clinical trial by UCL and University College Hospitals NHS Foundation Trust (UCLH) found that pembrolizumab (which can more than double the progres
-
Elderly women, sexual wasting half a year with fever, fatigue 8 days, please diagnose!
Time of Update: 2020-06-05
Oncology Department "Basic information" patients, female, 69 years old "main complaint" to carry out sexual wasting fever, fatigue 8 days "other examination" WBC: 19x 10 9/L, liver func
-
Sci Rep: Targeted therapy significantly inhibits breast cancer tumor growth in mice
Time of Update: 2020-06-05
June 2, 2020 /PRNewswire BIOON/ -- A team of researchers led by Wole Soboyejo, dean of the Worcester Institute of Technology (WPI), has identified a targeted drug that can reduce the size of in h
-
Brit J Cancer: The Relationship between Diabetes and Prostate Cancer Risk
Time of Update: 2020-06-05
In a recent study published in the journal British Journal of Cancer, the journal of the field of oncology, researchers looked forward to assessing the link between diabetes and prostate cancer ris
-
NAT CELL BIO: Liver cell aging secretions promote tumor development
Time of Update: 2020-06-05
To date, we are not fully aware of the interaction between liver cell metabolic disorders and cells in the tumor microenvironment, as well as the effects on liver tumors recently, researchers fou
-
Lancet: Higher mortality rate from new coronary pneumonia in cancer patients
Time of Update: 2020-06-05
Recently, researchers examined the COVID-19 burden in cancer patients and identified potential prognostic factors for mortality and serious diseases researchers collected data on new coronary pn
-
Trend in Cancer: Anticancer drugs make cancer cells resistant, and scientists develop new ways to stop the process!
Time of Update: 2020-06-05
June 4, 2020 / Biovalley BIOON / -- Cancer treatment can reduce the of tumors in patients, patients may feel better But what is not visible in CT scans or MR images is that some cells are undergo
-
Blood: Metabolic-based cancer treatment - Aldh3a2 inhibition
Time of Update: 2020-06-05
Metabolic changes in cancer represent the aggregate effect of cancer-causing mutations The researchers hypothesized that in an in vitro system that simulated a bone marrow microenvironment, the uni
-
Nature: Tumor metabolites hinder DNA repair! The reason is that local chromosome signals are disturbed!
Time of Update: 2020-06-05
June 5, 2020 / Biovalley BIOON/- Chromosomal abnormalities detected in the light mirror at the end of the 19th century revealed a massive genomic instability that caused abnormal chromosome number
-
ASCO 2020- Precision Treatment of Childhood Oncology Gets New Boost! Priority algorithm is feasible
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) has begun, and this academic feast has won the attention of oncologists around the world The most-watched summary of the
-
New drug for neuroblastoma! The new GD2 target antibody Danyelza was given priority by the FDA, and the total mitigation rate of the joint GM-CSF was as high as 78%!
Time of Update: 2020-06-05
June 04, 2020 / PRNewswire bioON/--Y-mAbs is a late-stage, clinical biopharmaceutical company dedicated to the development and commercialization of new, antibody-based cancer treatment products The
-
Cancer: Scientists develop new virus to attack cancer cells
Time of Update: 2020-06-05
June 5, 2020 / Biovalley BIOON / -- Adenoviruses are now better able to target and kill cancer cells thanks to the addition of RNA stabilization factors scientists at Hokkaido University in have
-
"Greedy" cancer cells: the energy produced by glycolysis to multiply and spread
Time of Update: 2020-06-05
Introduction: Sugar is the main food of cancer cells, sugar enters the body will be hydrolyzed into glucose, all our body's cells (including cancer cells) need glucose to provide energy Cancer cell